3-methylcholanthrene has been researched along with docetaxel anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Algarra, I; Chamorro, V; Collado, A; Garcia-Lora, AM; Garrido, C; Garrido, F; Romero, I | 1 |
| Goebel, S; Hoelzer, D; Leovsky, C; Meyer, FB; Spangel, SB; Thierbach, R | 1 |
2 other study(ies) available for 3-methylcholanthrene and docetaxel anhydrous
| Article | Year |
|---|---|
MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Fibrosarcoma; Histocompatibility Antigens Class I; Immunotherapy; Male; Methylcholanthrene; Mice, Inbred BALB C; Oligodeoxyribonucleotides; Polysaccharides | 2018 |
Metformin alters therapeutic effects in the BALB/c tumor therapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BALB 3T3 Cells; Carcinogens; Cell Survival; Cell Transformation, Neoplastic; Culture Media; Docetaxel; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Fluorouracil; Glucose; Humans; Metformin; Methylcholanthrene; Mice; Mitomycin; Neoplasms | 2021 |